Business
Clinical results from Phase I
Clinical results from Phase I.
About this update from Gunsynd Plc
[{"type":"text","content":"\n RNS Number : 3751C Syntopix Group plc 12 November 2009 \n\n\n\n\n\n\n\n\n\n12 November 2009\n\n\n\n\n\nSyntopix Group plc\n(\"Syntopix\" or \"the Company\")\n\nPositive clinical results from Phase II cosmetic study \n\nSyntopix Group plc (AIM:SYN), the speciality research and development company focused on the discovery of topical antimicrobials for healthcare and pharmaceutical applications, is pleased to announce positive results for its lead dermatological compound SYN0126, for the treatment of acneic skin, from a Phase II randomised, blinded cosmetic study in subjects with spot-prone skin. \n\nSYN0126 is a permitted cosmetic ingredient, which unlike the majority of prescription products already on the market, targets spots before redness sets in. Research was conducted in 70 subjects with impure skin who used formulations containing the Syntopix compound SYN0126, either alone or in combination with the Company's lipid-targeted antioxidant SYN0854, once daily for eight weeks. The trial demonstrated that formulations containing the Syntopix compounds produced a greater than 30% mean reduction in total spot count over an eight week period, outperforming a marketed cosmetic product containing 2% salicylic acid. The latter is a popular ingredient found in many cosmetic products and which was included in the Syntopix formulations. Both Syntopix formulations were well tolerated with good safety profiles.\n\nThe trial took place in Germany and started in January 2009. The study was randomised, blinded design with positive (marketed product) and negative (vehicle) controls. By the end of the study, the reduction in non-inflamed spots (comedones) was statistically highly significant for both of the Syntopix formulations and approaching the efficacy seen with a number of topical prescription treatments. In contrast, the negative control managed a mean reduction in non-inflamed spots of just 9.8% whilst the group using the marketed product (positive control) recorded a 7.8% mean increase. It is expected that a further Phase II cosmetic study will take place in the second half of 2...